Revenue

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

Shake Shack's lowered guidance reveals a consumer trading down from premium burgers, a worrying sign for the entire fast-casual industry's health.

Ahead of its token launch, nGRND has drawn 855k gamers with a novel promise: rewards backed by preserved, unmined gold. Is this the future of Web3?

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

At InfoComm 2026, Taiwan isn't just selling hardware. It's unveiling a national strategy to dominate the future of AI-driven enterprise technology.

While others chase fleeting trends, one Colorado agency built a decade of success on a radical idea: sustainability over scale. Here's the analysis.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

As Motorcar Parts of America preps its FY2026 report, investors await answers on declining revenue and the strategic review of its once-touted EV business.

A Canadian firm is betting big on natural hydrogen, a clean energy source found underground. With new funding and political clout, is this the future?

A new grant program for police tech seems simple, but Veritone's partnership with Police1 is a shrewd move to overcome the biggest sales hurdle: budget.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

JFrog's inclusion in the Russell 3000 isn't just a corporate win; it's a signal of the market's new respect for the software supply chain's vital role.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

An analysis of 89 school districts reveals a new data-driven playbook for reducing chronic absenteeism, with major implications for EdTech and human capital.

The 'better-for-you' brand is betting on a booming peanut butter market with its first non-chocolate snack, a strategic move backed by deep market data.

Browser innovator Shift renews its $25K Impact Grant, fueling sustainable startups as the tech industry grapples with its growing environmental footprint.

With an $18M Series A, Novellia is flipping the script on real-world data, empowering patients to solve a decades-old, multi-billion-dollar R&D bottleneck.